NOK 4.6
(-12.21%)
Year | Net Income | Net Income Growth |
---|---|---|
2023 | -45.51 Million NOK | -33.77% |
2022 | -34.02 Million NOK | 20.09% |
2021 | -42.57 Million NOK | -88.48% |
2020 | -22.59 Million NOK | -466.19% |
2019 | -3.98 Million NOK | -133.34% |
2018 | -1.7 Million NOK | 0.0% |
Year | Net Income | Net Income Growth |
---|---|---|
2024 Q2 | -11.75 Million NOK | 0.0% |
2024 Q1 | -11.75 Million NOK | 5.37% |
2023 Q4 | -12.42 Million NOK | 0.0% |
2023 FY | -45.51 Million NOK | -33.77% |
2023 Q1 | - NOK | 100.0% |
2023 Q3 | -12.42 Million NOK | 0.0% |
2023 Q2 | - NOK | 0.0% |
2022 Q4 | -9.53 Million NOK | 0.0% |
2022 FY | -34.02 Million NOK | 20.09% |
2021 FY | -42.57 Million NOK | -88.48% |
2020 FY | -22.59 Million NOK | -466.19% |
2019 FY | -3.98 Million NOK | -133.34% |
2018 FY | -1.7 Million NOK | 0.0% |
Name | Net Income | Net Income Difference |
---|---|---|
Aqua Bio Technology ASA | -19.11 Million NOK | -138.138% |
ArcticZymes Technologies ASA | 19.42 Million NOK | 334.31% |
BerGenBio ASA | -190.4 Million NOK | 76.095% |
Hofseth BioCare ASA | -106.68 Million NOK | 57.337% |
PCI Biotech Holding ASA | -20.31 Million NOK | -124.045% |
Thor Medical ASA | -26.56 Million NOK | -71.359% |
Ultimovacs ASA | -189.23 Million NOK | 75.949% |